USP9X
USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carcinoma, Sarcomas and 5 more.
Overview
Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin. Specifically hydrolyses 'Lys-11'-, followed by 'Lys-63'-, 'Lys-48'- and 'Lys-6'-linked polyubiquitins chains.
IntOGen calls it a driver in 7 cohorts (1 activating, 6 loss-of-function), covering Cholangiocarcinoma, Hepatocellular Carcinoma, Leiomyosarcoma, Nasopharyngeal Carcinoma, Prostate Adenocarcinoma, Well-Differentiated Thyroid Cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carcinoma, Sarcomas and 5 more.
- 1 · What it is
USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carcinoma, Sarcomas and 5 more.
- 2 · What goes wrong in cancer
Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins.
- 3 · How drugs use it
No product in this corpus aims at USP9X yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:12632 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q93008 (protein name, function text, keywords and locations (REST API)); IntOGen USP9X (driver in 7 cohorts (Act 1, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin. Specifically hydrolyses 'Lys-11'-, followed by 'Lys-63'-, 'Lys-48'- and 'Lys-6'-linked polyubiquitins chains. Essential component of TGF-beta/BMP signalling cascade. Specifically deubiquitinates monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein ligase TRIM33. Deubiquitinates alkylation repair enzyme ALKBH3. Location: Cytoplasm, cytosol; Cell projection, growth cone; Cytoplasm, cytoskeleton, cilium axoneme (UniProt). Locus Xp11.4 (HGNC).
- Thyroid cancer: IntOGen driver in 2 cohorts (WDTC)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Sarcomas: IntOGen driver in 1 cohort (LMS)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Papillary thyroid cancer: IntOGen driver in 2 cohorts (WDTC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 6 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"USP9X" OR ABSTRACT:"USP9X" OR TITLE:"ubiquitin specific peptidase 9 X-linked" OR ABSTRACT:"ubiquitin specific peptidase 9 X-linked" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase 9X" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase 9X" OR TITLE:"DFFRX" OR ABSTRACT:"DFFRX" OR TITLE:"FAF-X" OR ABSTRACT:"FAF-X" OR TITLE:"MRX99" OR ABSTRACT:"MRX99") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about USP9X, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMYH11
Shares Nasopharyngeal carcinoma, Biliary tract cancer (cholangiocarcinoma), Sarcomas (soft tissue, bone, GIST), IntOGen.
- TargetCOL2A1
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetPICALM
Shares Papillary thyroid cancer, Thyroid cancer, IntOGen.
- TargetWNK2
Shares Leiomyosarcoma, Sarcomas (soft tissue, bone, GIST), Hepatocellular carcinoma, IntOGen.
- TargetZNF429
Shares Biliary tract cancer (cholangiocarcinoma), Hepatocellular carcinoma, IntOGen, Prostate cancer.
- TargetCAMTA1
Shares Leiomyosarcoma, Sarcomas (soft tissue, bone, GIST), IntOGen, Prostate cancer.
- TargetPABPC1
Shares Papillary thyroid cancer, Thyroid cancer, Hepatocellular carcinoma, IntOGen.
- TargetCTNNA2
Shares Biliary tract cancer (cholangiocarcinoma), Hepatocellular carcinoma, IntOGen, Prostate cancer.